Phase 2 Multi-Center Study Of Tazemetostat (Epz-6438), An Inhibitor Of Enhancer Of Zeste-Homolog 2 (Ezh2), In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma (Nhl).

Franck Morschhauser,Gilles Salles,Steven Le Gouill,John Radford,Pamela McKay,Guillaume Cartron,Patricia Pimentel,Maria Roche,Stephen J. Blakemore,Alice McDonald,Natalie Warholic,Shelley Knight,Peter T.C. Ho,Vincent Ribrag

JOURNAL OF CLINICAL ONCOLOGY（2016）

Cited 11|Views46

No score

Abstract

TPS7582Background: The histone transferase EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) responsible for methylating lysine 27 of histone H3, a mark associated with repr...

Translated text

Key words

ezh2,tazemetostat,inhibitor,enhancer,multi-center,zeste-homolog,b-cell,non-hodgkin

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined